ESTRO 2024 - Abstract Book

S1401

Clinical - Head & neck

ESTRO 2024

Results:

The median age was 59 years (IQR, 53-64 years), most common primary tumor was squamous carcinoma (91.2%), the median follow-up was 15 months (IQR 11.2-18.7 months) and the median current follow-up was 18 months (95CI:16.3-19.6). No pts had G4 toxicity. The table 2 shows the toxicities at T2, T3 and T4. At T4 osteonecrosis and dysphonia was detected in 6.25% and 3.75 % of patients, respectively. The weight loss at the end of PBM (T2-T0) was statistically significant with a p-value of <0.01 (median 4.98;std 4.02; 95CI:4.08-5.87). The weight loss at T1/T2/T4 did not show statistical significance between Group A and Group B (p 0.887). In the analyses of oral pain at T2 continue variables show significantly with a p-value of 0.047 in the yes/no toxicities category. Group B developed significantly fewer ≥G2 toxicities compared to Group A with a p -value of <0.01. In T4 continue variables show a statistically significant in dysphagia and trismus with a p-value of 0.032 (OR 0.84; 95CI:0.71-0.98) and 0.047 (OR 0.77;95CI:0.60-0.99) respectively, in the yes/no toxicities category. In the analyses of dysphagia at T4, Group B developed significantly fewer ≥G2 toxicities compared to Group A with a p value of 0.020. The median local control (LC), metastasis free survival (MFS), disease-free survival (DFS) and overall survival (OS) was not reached and at 6 months, 12 months, 15 months were, respectively: 96.3%, 93.3% and 87.6% (LC), 95%, 91.3% and 89.3% (MFS), 92.5%, 89.6% and 82% (DFS), 98.8%, 98.8% and 97% (OS).

Conclusion: